Találati lista | Tudóstér

001-es BibID:	BIBFORM061604
Első szerző:	Csongrádi Éva (szakorvos)
Cím:	The Efficacy of Intravenous versus Subcutaneous Recombinant Erythropoietin in Obese African-African Patients in a Southeast U.S. Dialysis Cohort / Éva Csongrádi, Michael Shoemaker-Moyle, Lajos Zsom, Catherine Wells, Zsolt Lengvárszky, Mihály Tapolyai, Tibor Fülöp
Dátum:	2014
Megjegyzések:	Aims: To correct renal anemia, subcutaneous (SC) route of recombinant humanerythropoietin (rhuEPO) administration has been associated with increased efficacy anddecreased dose requirements, when compared with intravenous (IV) route. The effect ofobesity as a potential modifier during rhuEPO administration has not been well explored.Study Design: Single-center, Longitudinal Cohort Study.Place and Duration of Study: University of Mississippi Medical Center OutpatientDialysis Unit, between February and November of 2009.Methodology: We performed IV to SC rhuEPO conversion for 86 in-center dialysispatients and, following a six-month equilibration period, we monitored outcomes over aperiod of three months. We obtained baseline demographic parameters, calculated BodyMass Index (BMI) and monitored iron saturation, ferritin, hemoglobin (Hgb) along withrhuEPO requirements. Patients were divided into 3 categories based on BMI [<25 (n=27),25-35 (n=38), >35 (n= 21) kg/m2]. Results are reported either as percents, means with SDor median with 25-75% interquartile range, as appropriate.Results: The cohort was all African-American, 48.8% male, aged 54.7 (13.3) years andBMI calculated at 29.9 (7.4) kg/m2. Baseline iron saturation was 24 (10.6)%, ferritinmeasured 641 (277) ng/mL. Hgb remained unchanged during the observation period:11.1 (1.3) vs. 11.2 (1.3) gm/dL. Initial rhuEPO weekly dose for the entire cohort was19,729 (17,448) Units/week (U/week); final dose 17,482 (14,860) U/week, with closecorrelation between initial and final doses (r: 0.653, P<0.0001). Weekly rhuEPO doseremained virtually unchanged in BMI categories 1 and 2 [13,927 (10,938) vs. 13,297(10,247) U/week; 20,684 (15,788) vs. 20,997 (17.917)] (P=NS for both) but decreased inthe category 3: 25,459 (24,403) vs. 16,444 (12,749) (P=0.081). However, BMI had noindependent effect in linear regression modeling with multiple covariates (age, BMI, ironsaturation, ferritin) included.Conclusion: Obesity may affect relative efficacy of rhuEPO conversion; additionalstudies may be needed.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	British Journal of Medicine & Medical Research. - 4 : 1 (2014), p. 184-193. -
További szerzők:	Shoemaker-Moyle Michael (orvos) Zsom Lajos (1968-) (belgyógyász, nefrológus) Wells Catherine (tudományos segédmunkatárs) Lengvárszky Zsolt (matematikus informatikus) Tapolyai Mihály (1968-) (nefrológus) Fülöp Tibor (1957-) (kardiológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM113512
035-os BibID:	(scopus)85150972590 (wos)000956853000001
Első szerző:	Fayed, Ahmed
Cím:	Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study / Ahmed Fayed, Ahmed A. Hammad, Dina O. Abdulazim, Hany Hammad, Mohamed Amin, Samir Elhadidy, Mona M. Salem, Ibrahim M. Abd ElAzim, Lajos Zsom, Éva Csongradi, Karim M. Soliman, Usama A. Sharaf El Din
Dátum:	2023
ISSN:	0886-022X
Megjegyzések:	Background Patients with diabetic kidney disease (DKD) are at increased risk to develop post-contrast acute kidney injury (AKI). Diabetic patients under dipeptidyl peptidase 4 inhibitors (DPP4Is) experience a lower propensity to develop AKI. We speculated that linagliptin as a single agent or in combination with allopurinol may reduce the incidence of post-contrast AKI in stage 3-5 chronic kidney disease (CKD) patients with underlying DKD. Methods Out of 951 DKD patients eligible for this study, 800 accepted to sign informed consent. They were randomly allocated to 4 equal groups that received their prophylaxis for 2 days before and after radiocontrast. The first control group received N-acetyl cysteine and saline, the 2(nd) received allopurinol, the 3(rd) group received linagliptin, and the 4(th) received both allopurinol and linagliptin. Post-procedure follow-up for kidney functions was conducted for 2 weeks in all patients. Results 20, 19, 14, and 8 patients developed post-contrast AKI in groups 1 through 4, respectively. Neither linagliptin nor allopurinol was superior to N-acetyl cysteine and saline alone. However, the combination of the two agents provided statistically significant renal protection: post-contrast AKI in group 4 was significantly lower than in groups 1 and 2 (p < 0.02 and <0.03, respectively). None of the post-contrast AKI cases required dialysis. Conclusion Linagliptin and allopurinol in combination may offer protection against post-contrast AKI in DKD exposed to radiocontrast. Further studies are needed to support this view.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Renal Failure. - 45 : 1 (2023), p. p. 1-7. -
További szerzők:	Hammad, Ahmed A. Abdulazim, Dina O. Hammad, Hany Amin, Mohamed Elhadidy, Samir Salem, Mona M. ElAzim, Ibrahim M. Abd Zsom Lajos (1968-) (belgyógyász, nefrológus) Csongrádi Éva (1969-) (szakorvos) Soliman, Karim M. Sharaf El Din, Usama A.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: